135 related articles for article (PubMed ID: 12120711)
41. Ischaemic colitis in a patient taking meloxicam.
Garcia B; Ramaholimihaso F; Diebold MD; Cadiot G; Thiéfin G
Lancet; 2001 Mar; 357(9257):690. PubMed ID: 11247558
[TBL] [Abstract][Full Text] [Related]
42. Lipopolysaccharide modulates cyclooxygenase-2 transcriptionally and posttranscriptionally in human macrophages independently from endogenous IL-1 beta and TNF-alpha.
Barrios-Rodiles M; Tiraloche G; Chadee K
J Immunol; 1999 Jul; 163(2):963-9. PubMed ID: 10395693
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability.
Cipollone F; Prontera C; Pini B; Marini M; Fazia M; De Cesare D; Iezzi A; Ucchino S; Boccoli G; Saba V; Chiarelli F; Cuccurullo F; Mezzetti A
Circulation; 2001 Aug; 104(8):921-7. PubMed ID: 11514380
[TBL] [Abstract][Full Text] [Related]
44. [The effect of cyclooxygenase-2 inhibitor on acute lung injury].
Wang J; Mao B; Chen Z
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Jun; 22(6):351-3. PubMed ID: 11775825
[TBL] [Abstract][Full Text] [Related]
45. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
46. Involvement of FGF-2 in the action of Emdogain on normal human osteoblastic activity.
Mizutani S; Tsuboi T; Tazoe M; Koshihara Y; Goto S; Togari A
Oral Dis; 2003 Jul; 9(4):210-7. PubMed ID: 12974521
[TBL] [Abstract][Full Text] [Related]
47. [First i.m., now oral. COX-2 inhibitor in acute lumbago].
MMW Fortschr Med; 2002 Nov; 144(47):66. PubMed ID: 12532533
[No Abstract] [Full Text] [Related]
48. Pro-inflammatory IL-1beta and/or TNF-alpha up-regulate matrix metalloproteases-1 and -3 mRNA in chondrocyte subpopulations potentially pathogenic in osteoarthritis: in situ hybridization studies on a single cell level.
Kunisch E; Kinne RW; Alsalameh RJ; Alsalameh S
Int J Rheum Dis; 2016 Jun; 19(6):557-66. PubMed ID: 25291965
[TBL] [Abstract][Full Text] [Related]
49. MMP1-1607 polymorphism increases the risk for periapical lesion development through the upregulation MMP-1 expression in association with pro-inflammatory milieu elements.
Trombone AP; Cavalla F; Silveira EM; Andreo CB; Francisconi CF; Fonseca AC; Letra A; Silva RM; Garlet GP
J Appl Oral Sci; 2016; 24(4):366-75. PubMed ID: 27556208
[TBL] [Abstract][Full Text] [Related]
50. Cyclooxygenase-2 inhibition and cardiovascular events.
Pitt B; Pepine C; Willerson JT
Circulation; 2002 Jul; 106(2):167-9. PubMed ID: 12105151
[No Abstract] [Full Text] [Related]
51. In situ hybridization for matrix metalloproteinase-1 and cathepsin K in rat root-resorbing tissue induced by tooth movement.
Domon S; Shimokawa H; Matsumoto Y; Yamaguchi S; Soma K
Arch Oral Biol; 1999 Nov; 44(11):907-15. PubMed ID: 10580538
[TBL] [Abstract][Full Text] [Related]
52. Cyclooxygenase 2 pathway mediates IL-1beta regulation of IL-1alpha, -1beta, and IL-6 mRNA levels in Leydig cell progenitors.
Walch L; Morris PL
Endocrinology; 2002 Sep; 143(9):3276-83. PubMed ID: 12193539
[TBL] [Abstract][Full Text] [Related]
53. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model.
Hussey HJ; Tisdale MJ
Int J Cancer; 2000 Jul; 87(1):95-100. PubMed ID: 10861458
[TBL] [Abstract][Full Text] [Related]
54. Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
Martin CK; Dirksen WP; Carlton MM; Lanigan LG; Pillai SP; Werbeck JL; Simmons JK; Hildreth BE; London CA; Toribio RE; Rosol TJ
Vet Comp Oncol; 2015 Sep; 13(3):203-17. PubMed ID: 23651067
[TBL] [Abstract][Full Text] [Related]
55. Expression of the cyclooxygenase-2 gene in gastric epithelium.
Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Nakama A; Takei Y; Nagano K; Matsui H; Kawano S; Hori M
J Clin Gastroenterol; 1997; 25 Suppl 1():S105-10. PubMed ID: 9479635
[TBL] [Abstract][Full Text] [Related]
56. Regulation of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and extracellular metalloproteinase inducer by interleukin-17 in human periodontal ligament fibroblasts.
Wu Y; Zhu L; Wei H; Peng B
J Endod; 2013 Jan; 39(1):62-7. PubMed ID: 23228259
[TBL] [Abstract][Full Text] [Related]
57. Gingival crevicular fluid matrix metalloproteinase-8 levels following adjunctive use of meloxicam and initial phase of periodontal therapy.
Buduneli N; Vardar S; Atilla G; Sorsa T; Luoto H; Baylas H
J Periodontol; 2002 Jan; 73(1):103-9. PubMed ID: 11846190
[TBL] [Abstract][Full Text] [Related]
58. Cyclooxygenase-2 is upregulated in inflamed gingival tissues.
Morton RS; Dongari-Bagtzoglou AI
J Periodontol; 2001 Apr; 72(4):461-9. PubMed ID: 11338298
[TBL] [Abstract][Full Text] [Related]
59. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets.
Girod V; Dapzol J; Bouvier M; Grélot L
Neuropharmacology; 2002 Mar; 42(3):428-36. PubMed ID: 11897121
[TBL] [Abstract][Full Text] [Related]
60. [Rheumatic disease therapy without regret. Meloxicam dosage safety].
MMW Fortschr Med; 2002 Nov; 144(46):66-7. PubMed ID: 12534086
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
